Related Experiment Video
Updated: Jan 27, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Diagnostic accuracy of a fully automated multiplex celiac disease antibody panel for serum and plasma
Jeff Terryberry1, Jani Tuomi2, Subo Perampalam3
1SQI Diagnostics Systems Inc., 36 Meteor Dr. Toronto, ON M9W 1A4, Canada, Phone: +416-674-9500.
Insights
A new automated multiplex test for celiac disease (CD) improves diagnostic accuracy by measuring multiple antibodies. This method enhances the likelihood of confirming CD and monitoring gluten-free diet adherence.
Area of Science:
- Immunology
- Gastroenterology
- Clinical Diagnostics
Background:
- Celiac disease (CD) diagnosis can be improved with automated multiplex testing using capillary blood for higher throughput.
- Enhancing diagnostic accuracy through likelihood ratios for post-test probability is crucial for ruling in CD.
Purpose of the Study:
- To evaluate the diagnostic accuracy of the Ig_plex™ Celiac Disease Panel on the sqidlite™ automated platform.
- To compare multiplex antibody testing with conventional single antibody ELISA tests for celiac disease.
Main Methods:
- The Ig_plex™ Celiac Disease Panel measured IgA and IgG antibodies to tissue transglutaminase (tTG) and deamidated gliadin peptides (DGP) in 224 CD serum or plasma samples.
- Diagnostic accuracy metrics were applied to combined multiplex test results and compared to single antibody ELISA tests.
Main Results:
- Multiple positive antibody results increased the post-test probability of ruling in untreated and treated CD to over 90%.
- Measurement of all four CD antibodies generated accuracy profiles that can monitor gluten-free diet (GFD) treatment response.
- Positive tTG and DGP antibodies were more frequent in untreated CD (81%-94%) than treated CD (44%-64%).
- Plasma and serum agreement was high (≥98%), with 100% agreement between venous and capillary plasma.
Conclusions:
- The Ig_plex™ Celiac Disease Panel enhances CD confirmation likelihood via multi-reactive markers and post-test probability.
- Specific antibody positivity profiles and cut-off intervals aid in monitoring GFD treatment and disease progression.
- Serum, venous, and capillary plasma provide comparable and accurate results for celiac disease antibody testing.
Abstract:
Background An automated multiplex platform using capillary blood can promote greater throughput and more comprehensive studies in celiac disease (CD). Diagnostic accuracy should be improved using likelihood ratios for the post-test probability of ruling-in disease. Methods The Ig_plex™ Celiac Disease Panel on the sqidlite™ automated platform measured IgA and IgG antibodies to tTG and DGP in n = 224 CD serum or plasma samples. Diagnostic accuracy metrics were applied to the combined multiplex test results for several CD populations and compared to conventional single antibody ELISA tests. Results With multiple positive antibody results, the post-test probability for ruling-in untreated and treated CD increased to over 90%. The number of samples positive for more than one antibody also increased in untreated CD to ≥90%. Measurement of all four CD antibodies generate cut-off dependent accuracy profiles that can monitor response to treatment with the gluten-free diet (GFD). Higher positive tTG and DGP antibodies are seen more frequently in confirmed CD without (81%-94%) than with GFD treatment (44%-64%). In CD lacking biopsy confirmation, overall agreement of plasma to serum was ≥98% for all antibodies, and 100% for venous to capillary plasma. Conclusions The Ig_plex Celiac Disease Panel increases the likelihood of confirming CD based on the post-test probability of disease results for multi-reactive markers. Specific positivity profiles and cut-off intervals can be used to monitor GFD treatment and likely disease progression. Using serum, venous and capillary plasma yield comparable and accurate results.
More Related Videos
10:49Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
Published on: January 21, 2019
05:25Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023
Related Concept Videos
Wood Panel Products
Improving Translational Accuracy
Improving Translational Accuracy
Uncertainty in Measurement: Accuracy and Precision
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation